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ObjectivOs: El manejo de la artritis reumatoide (AR) implica grandes retos para 
los sistemas de salud, especialmente en países en vía de desarrollo, ya que exige la 
implementación de programas de atención integral para reducir el desgaste gradual, 
la complicación de síntomas y el impacto económico tanto a nivel familiar como 
del Estado. El objetivo del estudio fue construir una guía de intervención psicológica 
basada en la evidencia que facilite el ejercicio de psicólogos en la atención integral 
de pacientes diagnosticados con AR en Colombia. MetOdOlOgíAs: Se realizó una 
revisión sistemática de literatura y se formularon recomendaciones para el abordaje 
de factores psicológicos y sociales de la enfermedad a partir de la evidencia empírica 
hallada sobre la intervención psicológica para pacientes diagnosticados con AR. La 
inclusión de tales recomendaciones en la guía se logró a través de reuniones de 
consenso no estructurado con el grupo desarrollador; también fueron consideradas 
en el proceso las opiniones de expertos y de pacientes. Las recomendaciones fueron 
calificadas según los lineamientos de la Scottish Intercollegiate Guidelines Network 
(SIGN). ResultAdOs: Las prácticas recomendadas en esta guía se consolidaron en 
siete apartados: 1) psico-educación; 2) apoyo social; 3) estado de ánimo; 4) adher-
encia al tratamiento; 5) autoeficacia; 6) autocontrol - automanejo; y 7) manejo de 
dolor. La guía se encuentra lista para iniciar su validación e implementación en el 
ámbito clínico. cOnclusiOnes: Por primera vez, Colombia cuenta con una guía 
de intervención psicológica basada en la evidencia para la atención de pacientes 
con AR y el propósito final es que sea adoptada por el Sistema Nacional de Salud. 
El siguiente paso en el proceso de construcción de esta guía es su validación con 
expertos clínicos, pacientes, el Ministerio de Salud y otros actores del sistema de 
salud colombiano para hacer posible su diseminación y puesta en marcha.
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Objectives: To assess adverse events (AEs) and relapse rates in multiple sclerosis 
(MS) patients on Glatiramer Acetate (GA) treatment before and after the introduction 
of a purported generic GA (pgGA) in Mexico. MethOds: A pgGA was introduced 
in Mexico in January 2013. The dispensation decision of branded versus pgGA was 
made by each Pharmacy based on a predetermined national quota (40% pgGA in 
2013, 50% in 2014) and availability, allowing the same patient to receive both treat-
ments over time. Patient-reported data on AEs, relapses and pgGA or branded GA 
use were collected through branded GA’s Patient Support Program. Differences in 
outcomes during 2012 when only branded GA was available, and during February–
May of 2014 when mostly branded GA was dispensed (due to pgGA hold) were 
compared with outcomes in 2013 and during February–May in 2013, respectively 
(when both products were dispensed). Results: The total number of MS patients in 
the program during 2012, 2013 and 2014 were 1618, 1552, and 1755, respectively. The 
total number of AEs and relapses reported in 2013 were significantly higher (P< 0.05) 
than 2012. The total number of AEs and relapses in each month in 2013 (except in 1) 
was higher (AEs – 11 to 92, relapses – 1 to 13) than each of the corresponding 2012 
months (AEs – 4 to 26, relapses – 0 to 2). Comparing number of relapses adjusted 
by number of patients during February–May of 2014 to the same period in 2013, 
showed a decrease in relapses in this period in 2014 vs. 2013 (P< 0.035). Further 
research is needed to fully elucidate the underlying causes for the marked differ-
ences reported. cOnclusiOns: The observed increase in AEs and relapses in MS 
patients in Mexico raise questions about the interchangeability and comparability 
of pgGA to branded GA on treatment safety and efficacy.
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Objectives: Neisseria meningitidis is a leading cause of bacterial meningitis and 
septicemia in infants, young children and adolescents, with considerable morbidity 
and mortality and health system costs. We synthesized available data to estimate the 
cost associated with meningococcal disease in Brazil, Chile, Colombia, and Panama 
from the societal perspective. MethOds: National treatment guidelines were con-
sidered to establish treatment practices of meningococcal disease in each country. 
A combination of retrospective data collection techniques was used in the study, 
including structured interviews to physicians and primary caregivers, and review of 
patient medical records, and medical registers of hospitals, health centers and labo-
ratory centers. All cost components were based on 2014 prices and were converted 
to US dollars using the official exchange rate. Results: The economics of menin-
gococcal disease is complex and multifaceted. The country that reported the highest 
treatment cost of meningococcal disease was Panama, taking up 62% of the total 
cost across the three countries. This was followed by Colombia and Chile with both 
taking up to 22% and 16% of the total costs of meningococcal disease, respectively. 
Direct medical costs and, more specifically, hospital care costs took up the biggest 
proportion of the total cost of meningococcal disease in all three countries, rang-
ing from 63% to 72%, reflecting on the level of disease severity. Loss of productivity 
Objectives: There are no studies to our knowledge assessing, whether there are 
racial disparities related to total ankle arthroplasty (TAA) utilization and outcomes. 
Our objective was to study the racial disparities in total ankle arthroplasty (TAA) uti-
lization and outcomes. MethOds: We used the Nationwide Inpatient Sample (NIS) 
to study the time-trends. Race was categorized as White and Black. Utilization rates 
were calculated for the U.S. general population per 100,000. Hospital length of stay, 
discharge disposition and mortality after TAA were assessed. We used the Cochran 
Armitage trend test to assess time-trends from 1998 to 2011 and chi-square test to 
compare TAA utilization. We used analysis of variance or chi-squared test to compare 
the characteristics of Whites and Blacks undergoing TAA and logistic regression to 
compare mortality, length of stay and discharge to home vs medical facility. Results: 
The mean ages for Whites undergoing TAA were 62 years and for Blacks was 52 years. 
Significant racial disparities were noted in TAA utilization rates (/100,000) in 1998, 0.14 
in Whites vs. 0.07 in Blacks (p< 0.0001; 2-fold) and in 2011, 1.17 in Whites vs. 0.33 in 
Blacks (p< 0.0001; 4-fold). Racial disparities in TAA utilization increased significantly 
from 1998 to 2011 (p< 0.0001). There was a trend towards statistical significance in the 
length of hospital stay in Blacks vs. Whites (52.9% vs. 44.3% with length of hospital 
stay higher than the median; p= 0.08). Differences in the proportion discharged to 
an inpatient medical facility after TAA, 16% Blacks vs. 13% Whites, were not signifi-
cant (p= 0.47) cOnclusiOns: This study demonstrated significant racial disparities 
with lower TAA utilization and suboptimal outcomes in Blacks compared to Whites. 
Further studies are needed to understand the mediators of these disparities and to 
assess whether these mediators can be targeted to reduce racial disparities in TAA.
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ObjetivOs: estimar a prevalência da espondilite anquilosante para subsidiar para 
avaliações econômicas sobre a doença. MétOdOs: realizou-se uma revisão sis-
temática com estratégia de busca nas bases de dados Medline, via PUBMED, e The 
Cochrane Library no mês de março de 2014. A leitura dos títulos foi realizada em 
pares e as divergências dirimidas por consenso. Não foram aplicadas restrições 
quanto a idiomas e datas, sendo excluídos estudos que não eram transversais e 
àqueles que não apresentavam desfechos relacionados à prevalência da doença. A 
extração dos dados foi realizada por meio de formulário específico e revisada por um 
par antes de sua inclusão. A análise estatística foi realizada com auxílio do programa 
R 3.1.0. e para tal foi desenvolvido um gráfico de forest plot. ResultAdOs: foram 
encontrados 1.646, que após leitura de títulos foram selecionados 146, dos resumos 
26 e textos completos 14 estudos, sendo todos realizados fora do Brasil. A maio-
ria desses trabalhos (85,7%) foi desenvolvido em ambiente hospitalar. A amostra 
total foi de 266.194 participantes e a média ponderada obtida da prevalência foi de 
0,5649% (p< 0.001; IC: 95%), variando de 0,08% a 1,4%. Vale destacar que os méto-
dos utilizados para coletar a prevalência, assim como, os critérios de classificação 
da doença, foram bastante variados. Devido a essa grande heterogeneidade entre 
os estudos adotou-se, na análise estatística, a medida de efeito aleatório por ser 
mais apropriada e conservadora para esses casos. cOnclusões: De acordo com 
dados do estudo foi identificada elevada prevalência e dispersão da doença na 
população mundial, que impactam os orçamentos dos sistemas públicos de saúde. 
Considerando a importância da doença, e o impacto orçamentário de novos medi-
camentos são necessários mais estudos, especialmente no Brasil e na América do 
Sul uma vez que não foi detectado nenhum artigo que aborde o tema nesses países.
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Objectives: The study intended to assess the impact of educational intervention on 
knowledge of osteoporosis among female university students of Quetta. MethOds: 
This interventional study was conducted on female university students by using 
convenience sampling technique. A total of 163 female students were enrolled for 
the study, these are those female students who did not heard about the disease 
named as osteoporosis. These subjects were provided with a self-explanatory 
brochure that contain basic information regarding osteoporosis. The intervention 
was completely theoretical in nature. After two days interval participants were 
contacted again and asked to complete a pre-validated questionnaire containing 
20 questions related to osteoporosis knowledge. Descriptive analysis was used to 
demonstrate the demographic characteristics of the study population. Inferential 
statistics (Mann-Whitney U test and Kruskal Wallis tests and Wilcoxon mean rank 
test, p< 0.05) were used to assess the significance among study variables and to 
assess the impact of educational intervention on knowledge. Results: Average 
score of knowledge was 14.18±2.7 (20 max). The educational intervention had a 
significant effect on knowledge scores of the respondents (Wilcoxon rank test p< 
0.005) (considering the pre-intervention knowledge score as zero). Certain demo-
graphic characteristics (academic degree and living status) does affect knowledge 
scores of the study respondents. cOnclusiOns: Although adequate improvement 
of osteoporosis knowledge scores were reported after educational intervention, yet 
efforts should be made to bring change in the attitudes and practices of the female 
student by the help of intensive educational programs based on specified behavioral 
learning theories for better disease knowledge and prevention.
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the southern region of the USA had a higher costs compared to east, Midwest, and 
west regions (paid amount $3720 vs $3592 vs $3673 vs $2613). cOnclusiOns: The 
cost of Teriflunomide treatment for RRMS patients is higher and costing the health 
plan around $3552 per month. The cost of the drug treatment was higher in southern 
of the USA and males were paying more in general.
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Objectives: To assess the cost-effectiveness of natalizumab (NAT) as first-line 
treatment of Highly-Active Relapsing-Remitting Multiple Sclerosis (HARRMS) ver-
sus pooled interferon-beta (IFN) and glatiramer acetate (GA) from the Brazilian 
Public Healthcare (SUS) perspective. Natalizumab is currently only reimbursed for 
RRMS patients that failed therapy with IFN and GA. Currently, no guidance exist 
for patients with HARRMS in Brazil. MethOds: A microsimulation model was 
developed with yearly cycles over a 20-year time horizon. Four different treatment 
sequences are included in the model: T1= NAT-IFN-GA, T2= NAT-GA-IFN, T3= IFN-
GA-NAT and T4= GA-IFN-NAT, allowing treatment failures [i.e., > = 1-point increase 
in the Expanded Disability Status Scale (EDSS)] to alternate therapies. Patients may 
experience EDSS progression, relapses, remain stable, discontinue treatment, or 
die. Natural history was parameterized from the 2005 UK MS Survey. Efficacy, utili-
ties and safety/discontinuation data were derived from respective pivotal trials. 
HARRMS was defined as > 2 disabling relapses in previous year and > 1 gadolinium-
enhancing lesions or a significant increase in T2 lesions. Direct costs were from gov-
ernment reimbursement lists (i.e., DATASUS, BPS, SIGTAP), discounted at 5% yearly, 
and reported in Brazilian currency (1BRL= 0.35USD). Consequences were assessed 
in quality adjusted life years (QALY). Monte-Carlo first-order was used. Results: 
Natalizumab as first-line for HARRMS (sequences T1 and T2) was considered cost-
effective in comparison to sequences T3 and T4 (standard practice). Total costs 
(K= thousands) and QALYs for each treatment arm were: T4= BRL187K/5.43QALY, 
T3= BRL203K/5.41QALY, T2= BRL227K/7.02QALY and T1= BRL228K/7.01QALY. The 
incremental cost-effectiveness ratio (ICER) for T1 and T2 relative to the least costly 
sequence (T4) were BRL25,258/QALY and BRL26,324/QALY respectively, and consid-
ered acceptable assuming a threshold of 3x the national gross domestic product 
(GDP) per capita (~BRL70,000/QALY). cOnclusiOns: Since patients with HARRMS 
experience higher relapse rates and faster disability progression than the general 
RRMS population, natalizumab as first-line option is cost-effective and brings addi-
tional benefits to Brazilian patients.
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Objectives: Evaluate the costs and socioeconomic aspects of Immunoglobulin 
replacement therapy in patients with Primary Immunodeficiency (PID) treated 
at a Public health clinic in Brazil. MethOds: Transversal study with 42 patients 
who are being treated with intravenous immunoglobulin (IVIG) at the Division 
of Allergy Clinical Immunology and Rheumatology, Federal University Federal of 
São Paulo. Costs data were obtained from patient charts and Ministry of Health 
public reimbursement prices during the year of 2014. Socioeconomic data were 
obtained from a questionnaire answered by patients or their caregivers. A cost-
minimization modeling was performed comparing intravenous and subcutaneous 
routes. Results: Median patient age was 17 years old (6 months - 58 years) and 
71% were male. Mean IVIG dose was 639 mg/kg (400-1000 mg) under a 4 weeks 
regimen. Seventy-one percent of patients used public transportation, with mean 
daily expenditure (MDE) of R$ 19 and median duration of locomotion (MDL) of 4h 
(2:00-9:30); 25% used their own vehicle, with MDE of R$ 39 (0-100.00) and MDL of 
3:00h (0:45 to 4:45); 4% utilized an ambulance for transportation, with a MDL of 9:45h 
(5:00-14:30). Mean direct medical costs (drugs, infusion sets and health professional 
and administrative salaries) were R$ 2,298/patient/year for intravenous adminis-
tration. Thirteen school/ workdays were lost per year in this group, with a mean 
impact of RS 796/year/patient. Total cost (mean) of IVIG replacement was R$ 34,169/
patient/year while for subcutaneous route the cost calculated was R$ 32,245year (an 
R$ 1.833 difference). A 3 year cost minimization modeling comparing intravenous 
to subcutaneous route showed an average difference of R$ 1,128 per patient/year 
favoring the subcutaneous route. cOnclusiOns: This is first study evaluating the 
cost of immunoglobulin replacement therapy in PID patients in Brazil. The cost-
minimization analysis showed that the choice of subcutaneous route could bring 
benefits for the Public Health System.
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Objectives: To describe the profile of medicines procurement for Alzheimer’s 
disease (AD) in a Brazilian federal database. MethOds: This study investigated 
procurement of medicines for AD in the Sistema Integrado de Administração de 
Serviços Gerais (SIASG). A profile of purchases, expenditures and prices from 2008 
to 2013 was drawn. The following medicines used for treatment of AD — donepezil, 
galantamine, rivastigmine and memantine — in several dosage forms were investi-
gated, including those not present in the Brazilian guidelines (PCDT). The extracted 
contributed up to 2.4% of the total cost for meningococcal disease in Chile, in 
contrast to 1.7% and 1.3% of the total cost estimated in Colombia and Panama, 
respectively. cOnclusiOns: Findings of this study underscore the importance of 
meningococcal disease in the region in terms of cost. Future research should focus 
on more detailed investigation of costs of meningococcal cases and outbreaks from 
the societal perspective.
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Objectives: The objective of this study is to assess the health care costs associated 
with Disease Modifying Therapies (DMTs) for patients diagnosed with Relapsing 
Remitting Multiple Sclerosis (RRMS). MethOds: A large US administrative retro-
spective claims database was used to identify patients diagnosed with RRMS and 
were prescribed DMTs between January 2010 to December 2012 were included in 
the study. All patients were ≥ 18 years of age and continuously enrolled in the same 
health plan for at least a year. Descriptive statistics were performed on the data 
where appropriate. Results: There were a total of 741,065 patients that met the 
study inclusion criteria. Patients on average were charged $4161.40 ± 2817.59 for 
their DMTs treatment during the study period. However, the allowed amount by 
the health plan was $3681.33 ± 1847.82 and the actual paid amount was $3580.63 
± 1859.14. On average, patient’s deductible was $21.72 ± 228.50 and patient co-
payment was $82.94 ± 285.47. For patients whose prescription was on their health 
plans formulary paid on average higher costs compared to patients who were not 
(paid amount $3595 vs $3370; allowed amount $3686 vs 3493). Even though most 
of the patients were females, but they had overall lower costs compared to males 
(amount allowed $3677 vs $3689; paid amount $3576 vs $3590; deductible $21 vs $23; 
co-payment $82 vs $84). Patients who received treatment in the Midwest region of 
the USA had a higher costs compared to east, south, and west regions (paid amount 
$3672 vs $3596 vs $3468 vs $3461). cOnclusiOns: The mean cost of treatment with 
any DMTs for the treatment of RRMS patients is $4161. The drug formulary status 
did not play a role in determining overall healthcare costs. Females and patients 
from Midwest region generally had higher costs.
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Objectives: The objective of this study is to assess the health care resource utiliza-
tion and costs associated with Disease Modifying Therapies (DMTs) for pediatric 
patients diagnosed with Relapsing Remitting Multiple Sclerosis (RRMS). MethOds: 
A large US administrative retrospective claims database was used to identify 
patients diagnosed with RRMS and were prescribed DMTs between January 2010 to 
December 2012 were included in the study. All patients were ≤ 17 years of age and 
continuously enrolled in the same health plan at least for a year. Results: There 
were a total of 359 patients that met the study inclusion criteria and they were on 
the following DMTs: Gilenya (N= 7 (1.9%)), Extavia (N= 17 (4.7%)), Rebif (N= 32 (8.9%)), 
Copaxone (N= 117 (32.6%)), Avonex (N= 108 (30.1%)), and Betaseron (N= 78 (21.7%)). 
Patients on average were charged $3750.58 ± 1438.26 for their DMTs treatment dur-
ing the study period. However, the allowed amount by the health plan was $3547.05 
± 1380.56 and the actual paid amount was $3355.10 ± 1510.97. On average, patient’s 
deductible was $56.47 ± 401.03 and patient co-payment was $144.57 ± 371.65. For 
patients whose prescription was on their health plans formulary paid on average 
higher costs compared to patients who were not (paid amount $3406 vs $3223; 
allowed amount $3641 vs $3309). Even though most of the patients were females, 
but they had overall lower costs compared to males (amount allowed $3311 vs 
$3924; paid amount $3126 vs $3721; deductible $2.5 vs $155; co-payment $193 vs 
$66). Patients who received treatment in the east region of the USA had a higher 
costs compared to Midwest, south, and west regions (paid amount $3764 vs $3425 vs 
$3504 vs $3243). cOnclusiOns: Costs were high for males and formulary status of 
the DMTs did not have an impact on the amount paid by the patients.
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Objectives: The objective of this study is to assess the health care costs associ-
ated with Teriflunomide treatment for patients diagnosed with relapsing remitting 
multiple sclerosis (RRMS) in 2012 in the US MethOds: A large US administrative 
retrospective claims database was used to identify patients diagnosed with RRMS 
and were prescribed Terfilunomide between September 2012 to December 2012 were 
included in the study. All patients were ≥ 18 years of age and continuously enrolled 
in the same health plan for a year. Descriptive statistics and chi-square tests were 
performed on the data. Results: There were a total of 157 patients that met the 
study inclusion criteria. Patients on average were charged $3816.90 ± 1702.83 for 
their treatment with Teriflunomide during the study period. However, the allowed 
amount by the health plan was $3635.28 ± 1314.56 and the actual paid amount was 
$3552.75 ± 1320.71. On average, patient’s deductible was $12.81 ± 96.33 and patient 
co-payment was $84.66 ± 184.95. For patients whose prescription was on their health 
plans formulary were charged less but paid more on the deductible and co-payment 
compared to patients who were not (charged amount $3646 vs $3829; deductible $14 
vs $11; co-payment $122 vs $63) on the formulary. Even though most of the patients 
were females, but they had overall lower costs compared to males (amount allowed 
$3475 vs $4057; paid amount $3391 vs $3980). Patients who received treatment in 
